89bio stock hits 52-week low at $5.96 amid market challenges

In a challenging market environment, 89bio Inc . (NASDAQ:ETNB) stock has touched a 52-week low, reaching a price level of $5.96 USD. This significant downturn reflects a broader trend for the biopharmaceutical company, which has seen its stock price decline by 35.6% over the past year. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 13.2, though it’s currently experiencing rapid cash burn. Investors have been closely monitoring 89bio’s performance, as the company navigates through a period marked by volatility and uncertainty within the biotech sector. The 52-week low serves as a critical indicator for the company’s valuation and could potentially attract the attention of value investors looking for entry points in a beleaguered market segment. InvestingPro analysis suggests the stock is currently undervalued, with 4 analysts recently revising their earnings expectations upward. For deeper insights into 89bio’s valuation and prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, 89bio Inc. reported a strong financial position with $440 million in cash and cash equivalents at the end of last year, and it raised an additional $288 million earlier this quarter. Cantor Fitzgerald has maintained its Overweight rating on 89bio, with a price target of $29.00, reflecting confidence in the company’s clinical trial timelines and potential market impact. The firm noted that 89bio’s recent earnings and updated trial timelines have piqued investor interest, particularly in comparison to competitor Akero Therapeutics (NASDAQ:AKRO).

Meanwhile, H.C. Wainwright adjusted its price target for 89bio to $21, while maintaining a Buy rating. This adjustment follows the company’s decision to extend the unblinding schedule of its Phase 3 ENTRUST study for severe hypertriglyceridemia, with top-line data now expected in early 2026. Goldman Sachs initiated coverage of 89bio with a Neutral rating and an $11 price target, highlighting the potential of its lead candidate, pegozafermin, while adopting a cautious stance pending further data.

Additionally, 89bio’s Compensation Committee has awarded 200,000 restricted stock units to CEO Rohan Palekar as part of a retention strategy. These developments are part of the company’s ongoing efforts to advance its clinical programs and strengthen its leadership team. Investors continue to watch 89bio closely as it progresses toward potential commercialization of its treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.